The expression of ASAP3 and NOTCH3 and the clinicopathological characteristics of adult glioma patients

Ji, Min; Liu, Li; Sang, Wei; Xue, Jing; Wang, Bo; Pu, Hongwei; Zhang, Wei

doi:10.1515/med-2022-0585

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research revealed that the expression of Notch1 and Notch3 was significantly increased in glioblastoma and promoted tumor growth activity through the NF-κB pathway. 267 , 268 In addition, DLL3 was found to be up-regulated in IDH1 mutant gliomas and was associated with a better prognosis. 269 Overall, the differential expression pattern of Notch1–4 receptors can be used as a marker of glioma differentiation and a possible prognostic factor.…”

Section: The Notch Signaling Pathway and Cancermentioning

confidence: 99%

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

Shi,

Xue,

Zeng

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Notch signaling, renowned for its role in regulating cell fate, organ development, and tissue homeostasis across metazoans, is highly conserved throughout evolution. The Notch receptor and its ligands are transmembrane proteins containing epidermal growth factor-like repeat sequences, typically necessitating receptor-ligand interaction to initiate classical Notch signaling transduction. Accumulating evidence indicates that the Notch signaling pathway serves as both an oncogenic factor and a tumor suppressor in various cancer types. Dysregulation of this pathway promotes epithelial-mesenchymal transition and angiogenesis in malignancies, closely linked to cancer proliferation, invasion, and metastasis. Furthermore, the Notch signaling pathway contributes to maintaining stem-like properties in cancer cells, thereby enhancing cancer invasiveness. The regulatory role of the Notch signaling pathway in cancer metabolic reprogramming and the tumor microenvironment suggests its pivotal involvement in balancing oncogenic and tumor suppressive effects. Moreover, the Notch signaling pathway is implicated in conferring chemoresistance to tumor cells. Therefore, a comprehensive understanding of these biological processes is crucial for developing innovative therapeutic strategies targeting Notch signaling. This review focuses on the research progress of the Notch signaling pathway in cancers, providing in-depth insights into the potential mechanisms of Notch signaling regulation in the occurrence and progression of cancer. Additionally, the review summarizes pharmaceutical clinical trials targeting Notch signaling for cancer therapy, aiming to offer new insights into therapeutic strategies for human malignancies.

show abstract

Section: The Notch Signaling Pathway and Cancermentioning

confidence: 99%

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

Shi,

Xue,

Zeng

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection

Polano

Ius

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Background Glioma grade 4 (GG4) tumors, including astrocytoma IDH-mutant grade 4 and the astrocytoma IDH wt are the most common and aggressive primary tumors of the central nervous system. Surgery followed by Stupp protocol still remains the first-line treatment in GG4 tumors. Although Stupp combination can prolong survival, prognosis of treated adult patients with GG4 still remains unfavorable. The introduction of innovative multi-parametric prognostic models may allow refinement of prognosis of these patients. Here, Machine Learning (ML) was applied to investigate the contribution in predicting overall survival (OS) of different available data (e.g. clinical data, radiological data, or panel-based sequencing data such as presence of somatic mutations and amplification) in a mono-institutional GG4 cohort. Methods By next-generation sequencing, using a panel of 523 genes, we performed analysis of copy number variations and of types and distribution of nonsynonymous mutations in 102 cases including 39 carmustine wafer (CW) treated cases. We also calculated tumor mutational burden (TMB). ML was applied using eXtreme Gradient Boosting for survival (XGBoost-Surv) to integrate clinical and radiological information with genomic data. Results By ML modeling (concordance (c)- index = 0.682 for the best model), the role of predicting OS of radiological parameters including extent of resection, preoperative volume and residual volume was confirmed. An association between CW application and longer OS was also showed. Regarding gene mutations, a role in predicting OS was defined for mutations of BRAF and of other genes involved in the PI3K-AKT-mTOR signaling pathway. Moreover, an association between high TMB and shorter OS was suggested. Consistently, when a cutoff of 1.7 mutations/megabase was applied, cases with higher TMB showed significantly shorter OS than cases with lower TMB. Conclusions The contribution of tumor volumetric data, somatic gene mutations and TBM in predicting OS of GG4 patients was defined by ML modeling.

show abstract

The expression of ASAP3 and NOTCH3 and the clinicopathological characteristics of adult glioma patients

Cited by 2 publications

References 25 publications

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection

Contact Info

Product

Resources

About